Welcome to our dedicated page for Polaryx Therapeutics SEC filings (Ticker: PLYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Polaryx Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Polaryx Therapeutics's regulatory disclosures and financial reporting.
Polaryx Therapeutics, Inc. reported a net loss of approximately $2.5 million for the quarter ended March 31, 2026, narrower than the $5.1 million loss a year earlier. Operating expenses fell sharply as research and development declined to $679 thousand, mainly because a one-time, stock-based gene therapy license charge in 2025 did not recur.
General and administrative costs rose to $1.3 million, reflecting new public-company expenses and higher stock-based compensation to an advisor. Cash and cash equivalents were $3.1 million, with $2.1 million used in operating activities in the quarter and working capital of about $2.5 million as of March 31, 2026.
Polaryx remains a clinical-stage company with no product revenue and an accumulated deficit of roughly $102.2 million. Management discloses substantial doubt about its ability to continue as a going concern and expects existing cash to fund operations only through the third quarter of 2026, while it advances its PLX‑200 lysosomal storage disorder program toward a planned Phase 2 basket trial.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare pediatric lysosomal storage disorders, including neuronal ceroid lipofuscinoses (CLN2 and CLN3), Krabbe disease, Tay-Sachs and Sandhoff diseases, and Niemann-Pick disease types A and B.
The lead candidate PLX-200, an oral gemfibrozil-based formulation, has extensive preclinical data across multiple animal models, three FDA orphan drug designations and Fast Track status in select NCL indications, with a Phase 2 SOTERIA basket trial in four LSDs expected to start in the second half of 2026.
Additional programs include small molecules PLX-300 and PLX-100 and gene therapy PLX-400, all licensed primarily from Rush University Medical Center, supported by a services agreement with controlling stockholder Mstone. As of February 1, 2026, Polaryx had 47,343,297 common shares outstanding.
Polaryx Therapeutics, Inc. director and Chief Financial Officer Landis G. Michael reported an open-market purchase of common stock. On February 18, 2026, he bought 2,867 shares at an average price of $2.7871 per share, bringing his directly held stake to 228,225 shares.
Polaryx Therapeutics, Inc. received a Schedule 13D reporting that a group led by Mstone entities and Alex Keun Mo Yang beneficially owns 22,744,796 shares of common stock, or 48.0%, based on 47,343,297 shares outstanding as of January 12, 2026.
The group consists of Mstone Partners Healthcare Limited, MBstone Biotech Flagship Limited, Mstone Pediaorphan Singapore I Pte. Limited and Mr. Yang. Mstone holds 22,452,954 shares (47.4%), MBstone 183,560 shares (0.4%) and Mstone Singapore 108,282 shares (0.2%).
The aggregate purchase price for the currently owned shares is $3,000,513, funded from the reporting persons’ general working capital. Mr. Yang is Chief Executive Officer of Polaryx and has voting power over the shares held by the three Mstone entities, though he disclaims beneficial ownership outside Section 13(d) purposes. The group states it has no present specific plans for corporate actions but may reconsider its position over time.